Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma

Source :: Plus Company Updates. October 1, 2019
Publication Year :: 2019
Abstract: Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced that investigational, once-daily, fixed-dose inhaled QMF149 (indacaterol acetate and mometasone furoate or IND/MF) was superior to [...]

Subjects :: Novartis International AG -- Product development
Clinical trials
Mometasone -- Product development
Tiotropium -- Product development
Indacaterol
Pharmaceutical industry -- Product development
Asthma -- Care and treatment
Respiratory system agents
Glucocorticoids
General interest
News, opinion and commentary

Tools